US 10851093
Tyrosine kinase inhibitors
granted A61PA61P35/00
Quick answer
US patent 10851093 (Tyrosine kinase inhibitors) held by Rigel Pharmaceuticals, Inc. expires Mon Nov 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Rigel Pharmaceuticals, Inc.
- Grant date
- Tue Dec 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Nov 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 17
- CPC classes
- A61P, A61P35/00